A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine - Munjal, Sagar; Brand-Schieber, Elimor; Allenby, Kent; Spierings, Egilius L.H.; Cady, Roger K.; Rapoport, Alan M. (Journal of headache and pain, 2017)
Keywords: Administration, Intranasal; Adult; Drug Combinations; Drug therapy; Female; Humans; Internal Medicine; Male; Maltose - administration & dosage; Maltose - adverse effects; Maltose - analogs & derivatives; Maltose - pharmacology; Medicine; Medicine & Public Health; Middle Aged; Migraine; Migraine Disorders - drug therapy; Nasal Sprays; Neurology; Pain Medicine; Research Article; Safety; Studies; Sumatriptan - administration & dosage; Sumatriptan - adverse effects; Sumatriptan - pharmacology; Treatment Outcome; Vasoconstrictor Agents - administration & dosage; Vasoconstrictor Agents - adverse effects; Vasoconstrictor Agents - pharmacology; Young Adult; Acute treatment; Intranasal sumatriptan; Long-term safety; Episodic migraine; DDM; Sumatriptan